Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzagliatin and Sitagliptin interaction study in Type 2 Diabetes
NCT03790839Phase 1Completed
- Sponsor
- Hua Medicine
- Start
- Jan 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dorzagliatin in type 2 diabetes mellitus (T2DM), sponsored by Hua Medicine. Primary endpoints: Geometric mean ratio (GMR) for Cmax of sitagliptin up to 10 days, Geometric mean ratio (GMR) for AUC0-24h of sitagliptin up to 10 days and 6 more. Started Jan 2019; status: completed.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03790839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790839.